XenoPort and Patheon Ink Deal – Zacks.com

by admin on September 27, 2013

XenoPort and Patheon Ink Deal
Zacks.com
We note that Horizant is approved in the U.S. for the treatment of moderate-to-severe primary restless legs syndrome (RLS) as well as the management of postherpetic neuralgia (PHN) in adults. In May 2013, XenoPort resumed the supply and shipment of 

and more »

View full post on restless leg syndrome – Google News

Leave a Comment

Previous post:

Next post: